ABUS — Arbutus Biopharma Income Statement
0.000.00%
Last trade - 00:00- $629.97m
- $507.35m
- $6.17m
Annual income statement for Arbutus Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.91 | 11 | 39 | 18.1 | 6.17 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 64.7 | 84.5 | 104 | 96.2 | 82.5 |
| Operating Profit | -57.8 | -73.5 | -65.5 | -78.1 | -76.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -63.7 | -76.2 | -65 | -72.8 | -69.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -63.7 | -76.2 | -69.5 | -72.8 | -69.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -63.7 | -76.2 | -69.5 | -72.8 | -69.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -75.9 | -88.4 | -69.5 | -72.8 | -69.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1 | -0.832 | -0.46 | -0.439 | -0.357 |